Common heart medication shows promise against liver cancer
Liver cancer is the third-leading cause of cancer deaths worldwide, but a new study shows the solution to targeting this difficult-to-treat disease may already exist.
Oct 14, 2025
0
0
Heterocyclic Compounds: News and Research on Niacinamide
MeSH tree: D03.383.725.547.530
Targeted therapy overcomes cell plasticity in liver cancer mouse models
Researchers from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have made a significant advancement that could reshape the treatment landscape for hepatocellular carcinoma ...
Aug 13, 2025
0
9
Five-year survival in patients with unresectable hepatocellular carcinoma sets milestone
A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other localized treatments) ...
Jul 22, 2025
0
0
Treatment timing is critical to Prozac's impact on mood behaviors
Researchers have found that the timing of when fluoxetine (commonly known by its brand name, Prozac) is administered is vital in determining the impact it has on long-lasting mood behavior and accompanying changes in the ...
Jul 7, 2025
0
0
Liver cancer patients see longer survival with dual immunotherapy approach
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ipilimumab (NIVO+IPI)—in ...
Jun 16, 2025
0
44
FDA approves combo of Opdivo plus Yervoy for advanced liver cancer
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). The approval of Opdivo plus ...
Apr 16, 2025
0
0
How the chemotherapy drug sorafenib triggers muscle wasting through cell remodeling
Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side effects. One of these is severe muscle wasting, known as chemotherapy-induced cachexia. This chronic ...
Jan 23, 2025
0
22
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients
Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and ...
Dec 19, 2024
0
0
Some e-cigarette chemicals mimic nicotine, possibly bypassing regulation
In what appears to be an effort to bypass public health regulations covering vaping products, some tobacco companies have begun replacing nicotine in e-cigarettes with related chemicals that have similar properties but unknown ...
Aug 7, 2024
0
102
Combined therapy makes headway for liver cancer
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...
May 3, 2024
0
52
